

Breast Cancer[®]

U P D A T E

An Audio Review Journal for Surgeons
Bridging the Gap between Research and Patient Care

FACULTY INTERVIEWS

Harry D Bear, MD, PhD
Harold J Burstein, MD, PhD
Susan K Boolbol, MD
Ian E Smith, MD

EDITOR

Neil Love, MD

CONTENTS

2 Audio CDs

This activity provides Category 1 CME that may be used as self-assessment credit toward Part 2 of the American Board of Surgery MOC Program.



 Subscribe to Podcasts or download MP3s of this program at ResearchToPractice.com/BCUS115

 Follow us at Facebook.com/ResearchToPractice  Follow us on Twitter @DrNeilLove

Breast Cancer Update for Surgeons

A Continuing Medical Education Audio Series

OVERVIEW OF ACTIVITY

Historically, surgery has been the primary mode of treatment for early breast cancer. The diagnostic, surgical and medical management of breast cancer, however, has escalated in complexity because of numerous advances in novel technologies and available adjunctive therapies. Hence, the multifaceted treatment of breast cancer now requires the input of an interdisciplinary group of expert care providers. This paradigm shift has created the challenge of ensuring that knowledge of major clinical advances in local and systemic breast cancer therapy is effectively disseminated among all members of the cross-functional team. To bridge the gap between research and patient care, *Breast Cancer Update for Surgeons* uses one-on-one interviews with leading breast cancer investigators to efficiently distill the latest research developments so that they may be incorporated into clinical practice as appropriate. By providing access to cutting-edge data and expert perspectives, this CME program assists breast surgeons in the formulation of up-to-date clinical management strategies.

LEARNING OBJECTIVES

- Appreciate the similarities and differences among existing genomic assays, and use this information to select appropriate platform(s) to assess risk and individualize therapy for patients with early breast cancer.
- Develop an evidence-based approach to the management of the axilla in patients with localized breast cancer and a positive sentinel lymph node biopsy.
- Individualize the selection of evidence-based neoadjuvant and adjuvant chemobiologic regimens for patients with HER2-positive early breast cancer.
- Describe the importance of adequate surgical margins in mitigating local recurrence risk for women with early-stage invasive breast cancer treated with breast-conserving surgery.
- Counsel appropriately selected patients with breast cancer about participation in ongoing clinical trials.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this enduring material for a maximum of 2.75 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABS MAINTENANCE OF CERTIFICATION

This activity provides Category 1 CME that may be used as self-assessment credit toward Part 2 of the American Board of Surgery MOC Program. It is the responsibility of each individual to remain apprised of the current requirements for his or her board-specific MOC Program. For more information about the ABS MOC Program, visit www.absurgery.org.

HOW TO USE THIS CME ACTIVITY

This CME activity contains an audio component. To receive credit, the participant should review the CME information, listen to the CDs, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located in the back of this booklet or on our website at ResearchToPractice.com/BCUS115/CME.

This activity is supported by educational grants from Genentech BioOncology and Genomic Health Inc.

Release date: November 2015; Expiration date: November 2016

FACULTY INTERVIEWS



- 3 **Harry D Bear, MD, PhD**
Chairman, Division of Surgical Oncology
Professor of Surgery and Microbiology & Immunology
Walter Lawrence Jr Distinguished Professor in Oncology
Massey Cancer Center
Virginia Commonwealth University School of Medicine
Richmond, Virginia



- 3 **Harold J Burstein, MD, PhD**
Associate Professor of Medicine
Harvard Medical School
Breast Oncology Center
Dana-Farber Cancer Institute
Boston, Massachusetts



- 4 **Susan K Boolbol, MD**
Chief, Division of Breast Surgery
Chief, Appel-Venet Comprehensive Breast Service
Co-Director, Breast Surgery Fellowship
Mount Sinai Beth Israel
Associate Professor of Surgery
Icahn School of Medicine at Mount Sinai
New York, New York



- 4 **Ian E Smith, MD**
Professor of Cancer Medicine
Head of the Breast Unit
The Royal Marsden Hospital and Institute of Cancer Research
London, United Kingdom

5 SELECT PUBLICATIONS

6 POST-TEST

7 EDUCATIONAL ASSESSMENT AND CREDIT FORM

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

If you would like to discontinue your complimentary subscription to *Breast Cancer Update for Surgeons*, please email us at Info@ResearchToPractice.com, call us at (800) 648-8654 or fax us at (305) 377-9998. Please include your full name and address, and we will remove you from the mailing list.

EDITOR



Neil Love, MD
Research To Practice
Miami, Florida

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — **Dr Burstein** has no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: **Dr Bear** — Advisory Committee, Contracted Research and Speakers Bureau: Genomic Health Inc. **Dr Boolbol** — Speakers Bureau: Genentech BioOncology, Genomic Health Inc. **Dr Smith** — Advisory Committee: Pfizer Inc; Speakers Bureau: Eisai Inc.

EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bodesix Inc, bioTheragnostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

Have Questions or Cases You Would Like Us to Pose to the Faculty?



Submit them to us via Facebook or Twitter
and we will do our best to get them answered for you

 Facebook.com/ResearchToPractice or  Twitter @DrNeilLove

Interview with Harry D Bear, MD, PhD

Tracks 1-17

- Track 1** Perspective on skin-sparing and nipple-sparing mastectomy
- Track 2** Oncoplastic surgery to improve cosmetic outcomes
- Track 3** Role of margin status and re-excision in local recurrence after breast conservation surgery
- Track 4** Management of the axilla in patients with sentinel node metastasis
- Track 5** NSABP-B-39: A Phase III trial evaluating whole breast radiation therapy versus partial breast radiation therapy for women who have undergone surgery for ductal carcinoma in situ (DCIS) or Stage I/II breast cancer (BC)
- Track 6** **Case discussion:** A 50-year-old woman presents with a mass detected on self exam that is initially negative on breast imaging but is eventually diagnosed as high-grade, triple-negative, node-positive BC
- Track 7** Timing of sentinel node biopsy for patients receiving neoadjuvant therapy
- Track 8** Advantages of neoadjuvant chemotherapy
- Track 9** **Case discussion:** A 32-year-old woman with an 8-cm, high-grade, ER/PR-negative, HER2-positive, node-positive BC and a BRCA1 mutation achieves a dramatic response to neoadjuvant systemic therapy
- Track 10** NSABP-B-50-1 (KATHERINE): A Phase III trial of T-DM1 versus trastuzumab for women with HER2-positive BC who have residual tumor in the breast or axillary nodes
- Track 11** Axillary lymph node dissection (ALND) for patients with a positive sentinel node after neoadjuvant systemic therapy
- Track 12** **Case discussion:** A 60-year-old woman on long-term hormonal therapy presents with a 2-cm, ER/PR-positive, HER2-negative mass in the inferior aspect of the left breast
- Track 13** Use of the Oncotype DX® Recurrence Score® (RS) to guide adjuvant decision-making
- Track 14** Response to neoadjuvant therapy based on RS in patients with ER-positive, HER2-negative BC
- Track 15** An ongoing pilot study evaluating neoadjuvant hormone therapy versus chemotherapy for patients with ER/PR-positive, HER2-negative BC based on the Oncotype DX RS
- Track 16** **Case discussion:** A 48-year-old woman with ER/PR-positive, HER2-negative, node-positive, invasive ductal carcinoma (IDC) of the right breast and DCIS of the left breast is enrolled on the RxPONDER trial
- Track 17** RxPONDER: A Phase III trial of adjuvant endocrine therapy with or without chemotherapy for patients with node-positive BC and an RS of ≤ 25

Interview with Harold J Burstein, MD, PhD

Tracks 1-18

- Track 1** **Case discussion:** A 61-year-old woman with a 2.1-cm, ER/PR-positive, HER2-negative BC, a low Ki-67 score, 1 of 4 positive sentinel lymph nodes and an Oncotype DX RS of 17
- Track 2** Ki-67 as a prognostic marker in BC
- Track 3** Role of the Oncotype DX assay in predicting benefit from adjuvant chemotherapy
- Track 4** Value of the 21-gene RS in predicting chemotherapy benefit in patients with node-positive, ER-positive BC
- Track 5** Concordance among different genomic assays in identifying patients at low risk of recurrence
- Track 6** Clinical use of a scalp hypothermia system to prevent chemotherapy-induced alopecia
- Track 7** Role of adjuvant bisphosphonate therapy for patients with BC
- Track 8** Efficacy of the CDK 4/6 inhibitor palbociclib with letrozole as first-line or fulvestrant as second-line therapy for ER-positive, HER2-negative metastatic BC

Interview with Dr Burstein (continued)

Tracks 1-18

- Track 9** Tolerability and side effects of CDK 4/6 inhibitors
- Track 10** **Case discussion:** A 47-year-old woman with a 2.5-cm, ER-positive, PR-negative, HER2-positive IDC receives neoadjuvant paclitaxel/trastuzumab/pertuzumab
- Track 11** Perspective on the use of (neo)adjuvant pertuzumab
- Track 12** Effect of neoadjuvant therapy on breast conservation rates in triple-negative and HER2-positive BC
- Track 13** Adjuvant ovarian suppression in premenopausal women with BC
- Track 14** **Case discussion:** A 53-year-old woman with a 1.4-cm, Grade II, ER/PR-positive, HER2-negative BC and an *Oncotype* DX RS of 13 receives 5 years of adjuvant tamoxifen
- Track 15** Assessing recurrence risk prior to extending the duration of adjuvant endocrine therapy
- Track 16** **Case discussion:** A 68-year-old woman with atypical calcifications on a routine mammogram is diagnosed with intermediate-grade, ER-positive DCIS
- Track 17** Utility of the *Oncotype* DX assay for predicting local recurrence risk of DCIS
- Track 18** Primary results of NSABP-B-35: Anastrozole versus tamoxifen in postmenopausal patients with DCIS undergoing lumpectomy and radiation therapy

Interview with Susan K Boolbol, MD

Tracks 1-5

- Track 1** **Case discussion:** A 53-year-old woman who presents with a 0.9-cm, ER/PR-positive, HER2-negative IDC undergoes a partial mastectomy and pathology reveals positive margins and 1 of 2 positive sentinel nodes
- Track 2** Role of ALND in women with limited nodal disease
- Track 3** Perspective on ALND for patients undergoing a mastectomy
- Track 4** **Case discussion:** A 60-year-old woman with calcification of the right breast undergoes stereotactic biopsy and is diagnosed with DCIS
- Track 5** *Oncotype* DX DCIS Score™ as a tool for identifying risk of BC recurrence

Interview with Ian E Smith, MD

Tracks 1-7

- Track 1** **Case discussion:** A 64-year-old woman with ER/PR-positive, HER2-negative IDC presents 2 years after adjuvant therapy with supraclavicular nodal recurrence
- Track 2** Discordance in ER and HER2 between primary BC and metastasis
- Track 3** **Case discussion:** A 56-year-old woman with a strongly ER/PR-positive, HER2-negative, invasive lobular carcinoma and a low *Oncotype* DX RS
- Track 4** PALLET: A Phase II trial of palbociclib combined with letrozole as neoadjuvant therapy for ER-positive BC
- Track 5** **Case discussion:** A 36-year-old woman with a 5-cm, ER-negative, HER2-positive IDC achieves a pathologic complete response in the breast and axilla to neoadjuvant chemotherapy → trastuzumab/pertuzumab/taxane
- Track 6** Rationale for using pertuzumab in the adjuvant setting
- Track 7** Five-year analysis of NeoSphere: Addition of neoadjuvant pertuzumab to trastuzumab and/or docetaxel in locally advanced or inflammatory HER2-positive BC

SELECT PUBLICATIONS

A phase II randomized study evaluating the biological and clinical effects of the combination of palbociclib with letrozole as neoadjuvant therapy in post-menopausal women with estrogen-receptor positive primary breast cancer. [NCT02296801](#)

A phase III, randomized clinical trial of standard adjuvant endocrine therapy +/- chemotherapy in patients with 1-3 positive nodes, hormone receptor-positive and HER2-negative breast cancer with Recurrence Score (RS) of 25 or less. RxPONDER: A clinical trial Rx for positive node, endocrine responsive breast cancer. [NCT01272037](#)

A randomized, multicenter, open-label phase III study to evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy for patients with HER2-positive primary breast cancer who have residual tumor present pathologically in the breast or axillary lymph nodes following preoperative therapy. [NCT01772472](#)

A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer. [NCT00103181](#)

Adams BJ et al. The role of margin status and reexcision in local recurrence following breast conservation surgery. *Ann Surg Oncol* 2013;20(7):2250-5.

Albain KS et al. Prognostic and predictive value of the 21-gene Recurrence Score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. *Lancet Oncol* 2010;11(1):55-65.

Choosing neoadjuvant chemotherapy versus hormonal therapy for breast cancer based on gene expression profile. [NCT01293032](#)

Finn RS et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. *Lancet Oncol* 2015;16(1):25-35.

Francis PA et al. Adjuvant ovarian suppression in premenopausal breast cancer. *N Engl J Med* 2015;372(5):436-46.

Gianni L et al. Five-year analysis of the phase II NeoSphere trial evaluating four cycles of neoadjuvant docetaxel (D) and/or trastuzumab (T) and/or pertuzumab (P). *Proc ASCO* 2015;**Abstract 505**.

Giuliano AE et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: The American College of Surgeons Oncology Group Z0011 randomized trial. *Ann Surg* 2015;252(3):426-33.

Giuliano AE et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A randomized clinical trial. *JAMA* 2011;305(6):569-75.

Golshan M et al. Impact of neoadjuvant therapy on breast conservation rates in triple-negative and HER2-positive breast cancer: Combined results of CALGB 40603 and 40601 (Alliance). *Proc ASCO* 2015;**Abstract 1007**.

Margolese RG et al. Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy. *Proc ASCO* 2015;**Abstract LBA500**.

Moran MS et al; American Society for Radiation Oncology. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. *J Clin Oncol* 2014;32(14):1507-15.

Rakovitch E et al. A large prospectively-designed study of the DCIS score: Predicting recurrence risk after local excision for ductal carcinoma in situ patients with and without irradiation. San Antonio Breast Cancer Symposium 2014;**Abstract S5-04**.

Rugo H et al. Clinical performance of the DigniCap system, a scalp hypothermia system, in preventing chemotherapy-induced alopecia. *Proc ASCO* 2015;**Abstract 9518**.

Rutter CE et al. Influence of a 21-gene Recurrence Score assay on chemotherapy delivery in breast cancer. *Clin Breast Cancer* 2015;[Epub ahead of print].

Solin L et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. *J Natl Cancer Inst* 2013;105(10):701-10.

Turner NC et al. Palbociclib in hormone-receptor-positive advanced breast cancer. *N Engl J Med* 2015;373(3):209-19.

QUESTIONS (PLEASE CIRCLE ANSWER):

1. The SOFT trial evaluating ovarian suppression in premenopausal women with hormone receptor-positive BC demonstrated the following results with the addition of ovarian suppression to tamoxifen or exemestane versus tamoxifen alone:
 - a. A significant reduction in the risk of recurrence in the cohort who remained premenopausal after chemotherapy
 - b. A significant benefit with ovarian suppression in the cohort of women who did not receive chemotherapy
 - c. Both a and b
2. Palbociclib was recently approved by the FDA for use in combination with _____ as treatment for postmenopausal women with ER-positive, HER2-negative advanced BC in the first-line setting.
 - a. Letrozole
 - b. Fulvestrant
 - c. Tamoxifen
3. The results of a prospective trial of the scalp hypothermia system reported the technique to be highly effective with a success rate of approximately 70% in reducing chemotherapy-induced alopecia in women with Stage I/II BC receiving nonanthracycline-based neoadjuvant or adjuvant chemotherapy regimens.
 - a. True
 - b. False
4. The Oncotype DX assay for patients with DCIS who have undergone local excision predicts _____.
 - a. The risk of DCIS recurrence
 - b. The risk of invasive BC
 - c. Both a and b
5. The results of the ACOSOG Z0011 study evaluating ALND for women with T1-2 BC who have 1 to 2 positive sentinel nodes demonstrated a significantly lower locoregional recurrence rate with ALND.
 - a. True
 - b. False
6. Pertuzumab has been approved by the FDA for use in BC in the _____ setting.
 - a. Neoadjuvant
 - b. Adjuvant
 - c. Both a and b
7. Five-year analysis of the Phase II NeoSphere trial evaluating the addition of neoadjuvant pertuzumab to trastuzumab and/or docetaxel in locally advanced or inflammatory HER2-positive BC demonstrated that pertuzumab did not add any benefit in disease-free survival.
 - a. True
 - b. False
8. The Phase III RxPONDER study randomly assigns patients with hormone receptor-positive, HER2-negative BC with _____ and an Oncotype DX RS of 25 or lower to adjuvant endocrine therapy with or without chemotherapy.
 - a. Negative lymph nodes
 - b. One to 3 positive lymph nodes
 - c. Microscopically positive sentinel lymph node(s)
9. Results of the NSABP-B-35 trial of anastrozole versus tamoxifen in postmenopausal patients with DCIS undergoing lumpectomy and radiation therapy demonstrated _____.
 - a. A significant improvement in in-breast events with anastrozole
 - b. No difference in overall survival
 - c. No difference in the risk of contralateral invasive BC
 - d. All of the above
 - e. Both a and b
10. The Oncotype DX 21-gene RS _____ for patients with early-stage, node-negative, ER-positive invasive BC.
 - a. Predicts chemotherapy benefit
 - b. Predicts likelihood of distant BC recurrence
 - c. Both a and b
 - d. Neither a nor b

EDUCATIONAL ASSESSMENT AND CREDIT FORM

Breast Cancer Update for Surgeons — Issue 1, 2015

Research To Practice is committed to providing valuable continuing education for oncology clinicians, and your input is critical to helping us achieve this important goal. Please take the time to assess the activity you just completed, with the assurance that your answers and suggestions are strictly confidential.

PART 1 — Please tell us about your experience with this educational activity

How would you characterize your level of knowledge on the following topics?

4 = Excellent 3 = Good 2 = Adequate 1 = Suboptimal

	BEFORE	AFTER
Utility of the OncoType DX assay for predicting local recurrence risk in DCIS	4 3 2 1	4 3 2 1
NSABP-B-50-I (KATHERINE): A Phase III trial of T-DM1 versus trastuzumab for women with HER2-positive BC who have residual tumor in the breast or axillary nodes	4 3 2 1	4 3 2 1
Results of the NSABP-B-35 trial of anastrozole versus tamoxifen in patients with DCIS	4 3 2 1	4 3 2 1
RxPONDER: A Phase III trial of adjuvant endocrine therapy with or without chemotherapy for patients with node-positive BC and an RS of ≤25	4 3 2 1	4 3 2 1
Five-year analysis of the Phase II NeoSphere trial evaluating neoadjuvant docetaxel and/or trastuzumab and/or pertuzumab	4 3 2 1	4 3 2 1
Role of margin status and re-excision in local recurrence after breast conservation surgery	4 3 2 1	4 3 2 1

Practice Setting:

- Academic center/medical school
 Community cancer center/hospital
 Group practice
 Solo practice
 Government (eg, VA)
 Other (please specify).....

Approximately how many new patients with breast cancer do you see per year? patients

Was the activity evidence based, fair, balanced and free from commercial bias?

- Yes No

If no, please explain:

Please identify how you will change your practice as a result of completing this activity (select all that apply).

- This activity validated my current practice
 Create/revise protocols, policies and/or procedures
 Change the management and/or treatment of my patients
 Other (please explain):

If you intend to implement any changes in your practice, please provide 1 or more examples:

The content of this activity matched my current (or potential) scope of practice.

- Yes No

If no, please explain:

Please respond to the following learning objectives (LOs) by circling the appropriate selection:

4 = Yes 3 = Will consider 2 = No 1 = Already doing N/M = LO not met N/A = Not applicable

As a result of this activity, I will be able to:

- Appreciate the similarities and differences among existing genomic assays, and use this information to select appropriate platform(s) to assess risk and individualize therapy for patients with early breast cancer. 4 3 2 1 N/M N/A
- Develop an evidence-based approach to the management of the axilla in patients with localized breast cancer and a positive sentinel lymph node biopsy. 4 3 2 1 N/M N/A
- Individualize the selection of evidence-based neoadjuvant and adjuvant chemobiologic regimens for patients with HER2-positive early breast cancer. 4 3 2 1 N/M N/A
- Describe the importance of adequate surgical margins in mitigating local recurrence risk for women with early-stage invasive breast cancer treated with breast-conserving surgery. ... 4 3 2 1 N/M N/A
- Counsel appropriately selected patients with breast cancer about participation in ongoing clinical trials. 4 3 2 1 N/M N/A

EDUCATIONAL ASSESSMENT AND CREDIT FORM (continued)

Please describe any clinical situations that you find difficult to manage or resolve that you would like to see addressed in future educational activities:

.....

Would you recommend this activity to a colleague?

Yes No

If no, please explain:

PART 2 — Please tell us about the faculty and editor for this educational activity

4 = Excellent 3 = Good 2 = Adequate 1 = Suboptimal

Faculty	Knowledge of subject matter				Effectiveness as an educator			
Harry D Bear, MD, PhD	4	3	2	1	4	3	2	1
Harold J Burstein, MD, PhD	4	3	2	1	4	3	2	1
Susan K Boolbol, MD	4	3	2	1	4	3	2	1
Ian E Smith, MD	4	3	2	1	4	3	2	1
Editor	Knowledge of subject matter				Effectiveness as an educator			
Neil Love, MD	4	3	2	1	4	3	2	1

Please recommend additional faculty for future activities:

.....

Other comments about the faculty and editor for this activity:

.....

REQUEST FOR CREDIT — Please print clearly

Name: Specialty:

Professional Designation:

MD DO PharmD NP RN PA Other

Street Address: Box/Suite:

City, State, Zip:

Telephone: Fax:

Email:

Research To Practice designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

I certify my actual time spent to complete this educational activity to be _____ hour(s).

Signature: Date:

QID 1486

The expiration date for this activity is November 2016. To obtain a certificate of completion and receive credit for this activity, please complete the Post-test, fill out the Educational Assessment and Credit Form and fax both to (800) 447-4310, or mail both to Research To Practice, One Biscayne Tower, 2 South Biscayne Boulevard, Suite 3600, Miami, FL 33131. You may also complete the Post-test and Educational Assessment online at www.ResearchToPractice.com/BCUS115/CME.

Breast Cancer[®]

U P D A T E

Neil Love, MD
Research To Practice
One Biscayne Tower
2 South Biscayne Boulevard, Suite 3600
Miami, FL 33131

Copyright © 2015 Research To Practice.
This activity is supported by educational grants from
Genentech BioOncology and Genomic Health Inc.

Research To Practice[®]

Research To Practice is accredited by the Accreditation
Council for Continuing Medical Education to provide
continuing medical education for physicians.

Release date: November 2015
Expiration date: November 2016
Estimated time to complete: 2.75 hours



This program is printed on MacGregor XP paper, which is manufactured in
accordance with the world's leading forest management certification standards.

PRSR STD
U.S. POSTAGE
PAID
MIAMI, FL
PERMIT #1317